TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance

Target: TREM2 Composite Score: 0.524 Price: $0.00▼100.0% Citation Quality: 53% neuroscience Status: proposed Variant of GluN2B-Mediated Thalamocortical Control of Glympha

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔬 Microglial Biology 🔥 Neuroinflammation 🧠 Neurodegeneration 🔴 Alzheimer's Disease

✓ All Quality Gates Passed

Quality Report Card click to collapse

C+

Composite: 0.524

Top 74% of 1222 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.00) for Established

A Mech. Plausibility 15% 0.80 Top 21%

B Evidence Strength 15% 0.67 Top 37%

C+ Novelty 12% 0.50 Top 92%

C Feasibility 12% 0.47 Top 72%

C+ Impact 12% 0.51 Top 82%

B+ Druggability 10% 0.72 Top 31%

C+ Safety Profile 8% 0.50 Top 59%

C Competition 6% 0.45 Top 89%

A Data Availability 5% 0.80 Top 19%

A Reproducibility 5% 0.89 Top 15%

Evidence

16 supporting | 3 opposing

Citation quality: 75%

Debates

1 session A+

Avg quality: 0.95

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Circuit-level neural dynamics in neurodegeneration

Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit disruption, (2) cortical dynamics alterations, (3) sensory processing changes. Identify circuit-based therapeutic targets connecting genes, proteins, and brain regions to neurodegeneration phenotypes.

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment to restore hippocampal-cortical connectivity in early MCI

Score: 1.000 | Target: PVALB

Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal gamma oscillations via upstream perforant path gating in Alzheimer's disease

Score: 0.948 | Target: SST

Closed-loop optogenetic targeting PV interneurons to restore theta-gamma coupling and prevent amyloid-induced synaptic dysfunction in AD

Score: 0.944 | Target: PVALB

Closed-loop focused ultrasound targeting CA1 PV interneurons to restore theta-gamma coupling and block synaptotoxic Aβ oligomers in AD

Score: 0.927 | Target: PVALB

Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to prevent tau propagation and restore entorhinal-hippocampal gamma synchrony in early Alzheimer's disease

Score: 0.922 | Target: SST

Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via cholecystokinin interneuron neuromodulation in Alzheimer's disease

Score: 0.912 | Target: CCK

Closed-loop focused ultrasound targeting EC-II SST interneurons to restore gamma gating and block tau propagation in AD

Score: 0.900 | Target: SST

Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and restore perforant-path gamma gating in AD

Score: 0.896 | Target: SST

→ View full analysis & all 9 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance starts from the claim that modulating TREM2 within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance starts from the claim that modulating TREM2 within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "This hypothesis proposes that TREM2-mediated microglial signaling serves as the master regulator of thalamocortical oscillatory networks that drive glymphatic tau clearance. The mechanistic framework centers on TREM2/DAP12 signaling in perivascular microglia directly modulating the function of extrasynaptic GluN2B receptors in thalamocortical circuits through microglial cytokine release and synaptic pruning. When TREM2 signaling is intact, microglia maintain optimal thalamocortical connectivity by selectively preserving GluN2B-containing synapses while clearing tau aggregates, ensuring robust gamma oscillations that drive coordinated astrocytic calcium waves and proper AQP4 polarization at perivascular endfeet. However, when TREM2/DAP12 signaling is impaired, microglia become dysfunctional in a dual manner: they fail to clear accumulating tau deposits through compromised Syk-PI3K pathways, and simultaneously over-prune critical GluN2B synapses, leading to collapsed thalamocortical synchrony. This creates a devastating cascade where loss of oscillatory drive eliminates the rhythmic astrocytic calcium signaling required for AQP4 clustering, while accumulated tau deposits physically obstruct perivascular clearance pathways. The resulting glymphatic dysfunction creates a positive feedback loop where impaired tau clearance further disrupts network oscillations. This mechanism explains why TREM2 variants confer such strong tauopathy risk and why sleep disturbances accelerate tau pathology - both involve the same TREM2-thalamocortical-glymphatic axis. The hypothesis predicts that selective TREM2 agonists will simultaneously restore microglial tau clearance, preserve GluN2B-mediated oscillations, and reestablish glymphatic flow, making this pathway an ideal therapeutic target for addressing the convergent network and clearance dysfunctions in tauopathies." Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neuroscience. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating TREM2 or the surrounding pathway space around TREM2/DAP12-thalamocortical-glymphatic axis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.67, novelty 0.50, feasibility 0.47, impact 0.51, mechanistic plausibility 0.80, and clinical relevance 0.51. ## Molecular and Cellular Rationale The nominated target genes are `TREM2` and the pathway label is `TREM2/DAP12-thalamocortical-glymphatic axis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context GRIN2B: - GRIN2B (Glutamate Ionotropic Receptor NMDA Type Subunit 2B, also known as GluN2B/NR2B) is a subunit of NMDA receptors that determines receptor kinetics, Mg2+ sensitivity, and downstream signaling specificity. GRIN2B-containing NMDA receptors are critical for synaptic plasticity, learning, and memory. Allen Human Brain Atlas shows high expression in hippocampus, cortex, and thalamus, peaking during early development. In AD, GRIN2B expression is reduced in hippocampus and cortex, contributing to impaired NMDA-dependent LTP and cognitive decline. Extrasynaptic GRIN2B-NMDAR activation promotes excitotoxicity and amyloid-beta oligomer signaling. - Datasets: Allen Human Brain Atlas, SEA-AD snRNA-seq, GTEx Brain v8, Mathys et al. 2019 - Expression Pattern: Neuron-specific; highest in hippocampal pyramidal neurons and cortical layers II-III; developmental peak then sustained adult expression; synaptic and extrasynaptic pools Cell Types: - Excitatory pyramidal neurons (highest) - Inhibitory interneurons (moderate) - Hippocampal CA1 pyramidal neurons (very high) - Not expressed in glia Key Findings: 1. GRIN2B mRNA reduced 30-50% in AD hippocampus vs age-matched controls (SEA-AD) 2. Extrasynaptic GRIN2B-NMDAR activation by Abeta oligomers triggers calcineurin-dependent synaptic depression 3. GRIN2B/GRIN2A ratio decreases with age and further in AD, shifting NMDA signaling toward faster kinetics 4. Memantine selectively blocks extrasynaptic NMDARs, partially rescuing AD cognitive deficits 5. GRIN2B dephosphorylation at Tyr1472 reduces synaptic NMDAR surface expression in AD Regional Distribution: - Highest: Hippocampus CA1-CA3, Prefrontal Cortex Layers II-III, Entorhinal Cortex - Moderate: Temporal Cortex, Cingulate Cortex, Thalamus - Lowest: Cerebellum (GRIN2A dominant), Brainstem, Spinal Cord This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of TREM2 or TREM2/DAP12-thalamocortical-glymphatic axis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Thalamocortical circuit integrity differentiates normal aging from mild cognitive impairment, with decreased neural complexity and increased synchronization being hallmarks of dysfunction. Identifier 19449329. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. NMDA receptor function is required for Aβ-induced synaptic depression, indicating these receptors are key mediators of circuit dysfunction. Identifier 23431156. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. GluN2B subunits play distinct roles in visual cortical plasticity. Identifier 26282667. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil. Identifier 40994429. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Cognitive loss after brain trauma results from sex-specific activation of synaptic pruning processes. Identifier 40796363. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Aberrant mRNA splicing and impaired hippocampal neurogenesis in Grin2b mutant mice. Identifier 41675057. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunction rather than improve it. Identifier 30352630. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Epigenetics in Learning and Memory. Identifier 39820860. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Identifier 37369776. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `None`, debate count `3`, citations `19`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting TREM2 within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neuroscience. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating TREM2 or the surrounding pathway space around TREM2/DAP12-thalamocortical-glymphatic axis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.67, novelty 0.50, feasibility 0.47, impact 0.51, mechanistic plausibility 0.80, and clinical relevance 0.51.

Molecular and Cellular Rationale

The nominated target genes are `TREM2` and the pathway label is `TREM2/DAP12-thalamocortical-glymphatic axis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context GRIN2B: - GRIN2B (Glutamate Ionotropic Receptor NMDA Type Subunit 2B, also known as GluN2B/NR2B) is a subunit of NMDA receptors that determines receptor kinetics, Mg2+ sensitivity, and downstream signaling specificity. GRIN2B-containing NMDA receptors are critical for synaptic plasticity, learning, and memory. Allen Human Brain Atlas shows high expression in hippocampus, cortex, and thalamus, peaking during early development. In AD, GRIN2B expression is reduced in hippocampus and cortex, contributing to impaired NMDA-dependent LTP and cognitive decline. Extrasynaptic GRIN2B-NMDAR activation promotes excitotoxicity and amyloid-beta oligomer signaling. - Datasets: Allen Human Brain Atlas, SEA-AD snRNA-seq, GTEx Brain v8, Mathys et al. 2019 - Expression Pattern: Neuron-specific; highest in hippocampal pyramidal neurons and cortical layers II-III; developmental peak then sustained adult expression; synaptic and extrasynaptic pools Cell Types: - Excitatory pyramidal neurons (highest) - Inhibitory interneurons (moderate) - Hippocampal CA1 pyramidal neurons (very high) - Not expressed in glia Key Findings: 1. GRIN2B mRNA reduced 30-50% in AD hippocampus vs age-matched controls (SEA-AD) 2. Extrasynaptic GRIN2B-NMDAR activation by Abeta oligomers triggers calcineurin-dependent synaptic depression 3. GRIN2B/GRIN2A ratio decreases with age and further in AD, shifting NMDA signaling toward faster kinetics 4. Memantine selectively blocks extrasynaptic NMDARs, partially rescuing AD cognitive deficits 5. GRIN2B dephosphorylation at Tyr1472 reduces synaptic NMDAR surface expression in AD Regional Distribution: - Highest: Hippocampus CA1-CA3, Prefrontal Cortex Layers II-III, Entorhinal Cortex - Moderate: Temporal Cortex, Cingulate Cortex, Thalamus - Lowest: Cerebellum (GRIN2A dominant), Brainstem, Spinal Cord This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of TREM2 or TREM2/DAP12-thalamocortical-glymphatic axis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Thalamocortical circuit integrity differentiates normal aging from mild cognitive impairment, with decreased neural complexity and increased synchronization being hallmarks of dysfunction. Identifier 19449329. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

NMDA receptor function is required for Aβ-induced synaptic depression, indicating these receptors are key mediators of circuit dysfunction. Identifier 23431156. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

GluN2B subunits play distinct roles in visual cortical plasticity. Identifier 26282667. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil. Identifier 40994429. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Cognitive loss after brain trauma results from sex-specific activation of synaptic pruning processes. Identifier 40796363. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Aberrant mRNA splicing and impaired hippocampal neurogenesis in Grin2b mutant mice. Identifier 41675057. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunction rather than improve it. Identifier 30352630. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Epigenetics in Learning and Memory. Identifier 39820860. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Identifier 37369776. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `None`, debate count `3`, citations `19`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TREM2 within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["GluN2B NMDA Receptor
Extrasynaptic Expression"] --> B["Calcium Influx
Ca2+ Permeable Channel"]
    B --> C["CaMKII Activation
Calcium-Dependent Kinase"]
    C --> D["CREB Phosphorylation
Transcription Factor"]
    D --> E["Synaptic Plasticity Genes
LTP Enhancement"]
    
    A --> F["Thalamic Relay Neurons
VB and VPM Nuclei"]
    F --> G["Cortical Layer IV
Sensory Input Processing"]
    G --> H["Pyramidal Neurons
Layer V Output"]
    
    A --> I["Gamma Oscillations
40-100 Hz Frequency"]
    I --> J["Theta Oscillations
4-8 Hz Frequency"]
    J --> K["Thalamocortical Synchrony
Network Coordination"]
    
    L["GluN2B Positive Modulator
Therapeutic Intervention"] --> A
    L --> M["Enhanced NMDA Function
Prolonged Deactivation"]
    M --> N["Sustained Depolarization
Temporal Integration"]
    N --> K
    
    O["Neurodegeneration
Pathological State"] --> P["Reduced GluN2B Expression
Receptor Downregulation"]
    P --> Q["Disrupted Oscillations
Loss of Synchrony"]
    Q --> R["Cognitive Impairment
Functional Outcome"]

classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8

class A,B,C,D,E,M,N normal
class L therapeutic
class O,P,Q pathology
class R outcome
class F,G,H,I,J,K molecular

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

19 citations 19 with PMID Validation: 75% 16 supporting / 3 opposing

✓ For (16)

No supporting evidence

No opposing evidence

(3) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 8CLIN 2GENE 9EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Thalamocortical circuit integrity differentiates n…	Supporting	MECH	-	-	-	-	PMID:19449329	-
NMDA receptor function is required for Aβ-induced …	Supporting	MECH	-	-	-	-	PMID:23431156	-
GluN2B subunits play distinct roles in visual cort…	Supporting	MECH	-	-	-	-	PMID:26282667	-
Inhibition of GluN2B-containing N-methyl-D-asparta…	Supporting	GENE	Brain	-	2026	-	PMID:40994429	-
Cognitive loss after brain trauma results from sex…	Supporting	GENE	Brain	-	2026	-	PMID:40796363	-
Aberrant mRNA splicing and impaired hippocampal ne…	Supporting	GENE	iScience	-	2026	-	PMID:41675057	-
From synapse to system: mechanistic pathways of ne…	Supporting	GENE	Front Cell Dev …	-	2026	-	PMID:41799440	-
GluN2B-specific NMDAR positive allosteric modulati…	Supporting	GENE	Sci Adv	-	2026	-	PMID:41512078	-
Multi-biofluid metabolomics coupled with gene netw…	Supporting	CLIN	Brain Res	-	2026	-	PMID:41534821	-
Multisession epidural direct current stimulation o…	Supporting	MECH	Hear Res	-	2026	-	PMID:41747412	-
Zipper-interacting Protein Kinase Modulates Gene E…	Supporting	GENE	Mol Neurobiol	-	2026	-	PMID:41526727	-
Inspired by molecular dynamic simulation, explorin…	Supporting	MECH	J Biomol Struct…	-	2026	-	PMID:40166865	-
Cellular Prion Protein Engages the N-Methyl-d-Aspa…	Supporting	MECH	Biochemistry	-	2026	-	PMID:41860118	-
Molecular mechanism of ligand gating and opening o…	Supporting	GENE	Nature	-	2024	-	PMID:39085540	-
Mechanism of conductance control and neurosteroid …	Supporting	GENE	Nature	-	2025	-	PMID:41162707	-
Synaptic rearrangement of NMDA receptors controls …	Supporting	MECH	Sci Adv	-	2024	-	PMID:39213354	-
NMDA receptors mediate synaptic depression in amyl…	Opposing	MECH	-	-	-	-	PMID:30352630	-
Epigenetics in Learning and Memory.	Opposing	GENE	Subcell Biochem	-	2025	-	PMID:39820860	-
Therapeutic potential of N-methyl-D-aspartate rece…	Opposing	CLIN	Neuropsychophar…	-	2024	-	PMID:37369776	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 16

Thalamocortical circuit integrity differentiates normal aging from mild cognitive impairment, with decreased n…▼

Thalamocortical circuit integrity differentiates normal aging from mild cognitive impairment, with decreased neural complexity and increased synchronization being hallmarks of dysfunction

PMID:19449329

NMDA receptor function is required for Aβ-induced synaptic depression, indicating these receptors are key medi…▼

NMDA receptor function is required for Aβ-induced synaptic depression, indicating these receptors are key mediators of circuit dysfunction

PMID:23431156

GluN2B subunits play distinct roles in visual cortical plasticity

PMID:26282667

Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil.

Brain · 2026 · PMID:40994429

Cognitive loss after brain trauma results from sex-specific activation of synaptic pruning processes.

Brain · 2026 · PMID:40796363

Aberrant mRNA splicing and impaired hippocampal neurogenesis in Grin2b mutant mice.

iScience · 2026 · PMID:41675057

From synapse to system: mechanistic pathways of neural signaling dysfunction in psychiatric disorders.

Front Cell Dev Biol · 2026 · PMID:41799440

GluN2B-specific NMDAR positive allosteric modulation reverses cognitive and behavioral abnormalities in Mecp2 …▼

GluN2B-specific NMDAR positive allosteric modulation reverses cognitive and behavioral abnormalities in Mecp2 and Disc1 transgenic mice.

Sci Adv · 2026 · PMID:41512078

Multi-biofluid metabolomics coupled with gene network reveals stage-specific alterations in mild cognitive imp…▼

Multi-biofluid metabolomics coupled with gene network reveals stage-specific alterations in mild cognitive impairment and Alzheimer's disease in an ethnically mixed cohort.

Brain Res · 2026 · PMID:41534821

Multisession epidural direct current stimulation of the auditory cortex mitigates age-related transcriptomic d…▼

Multisession epidural direct current stimulation of the auditory cortex mitigates age-related transcriptomic dysregulation in Wistar rats.

Hear Res · 2026 · PMID:41747412

Zipper-interacting Protein Kinase Modulates Gene Expression Linked to Synaptic and Neuronal Processes after Tr…▼

Zipper-interacting Protein Kinase Modulates Gene Expression Linked to Synaptic and Neuronal Processes after Traumatic Brain Injury.

Mol Neurobiol · 2026 · PMID:41526727

Inspired by molecular dynamic simulation, exploring chemical constituents of alcoholic extract of Garuga pinna…▼

Inspired by molecular dynamic simulation, exploring chemical constituents of alcoholic extract of Garuga pinnata computationally as inhibitors of GluN2B-containing NMDA receptors.

J Biomol Struct Dyn · 2026 · PMID:40166865

Cellular Prion Protein Engages the N-Methyl-d-Aspartate Receptor through N- and C-Terminal Domains.

Biochemistry · 2026 · PMID:41860118

Molecular mechanism of ligand gating and opening of NMDA receptor.

Nature · 2024 · PMID:39085540

Mechanism of conductance control and neurosteroid binding in NMDA receptors.

Nature · 2025 · PMID:41162707

Synaptic rearrangement of NMDA receptors controls memory engram formation and malleability in the cortex.

Sci Adv · 2024 · PMID:39213354

✗ Opposing Evidence 3

NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunc…▼

NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunction rather than improve it

PMID:30352630

Epigenetics in Learning and Memory.

Subcell Biochem · 2025 · PMID:39820860

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.

Neuropsychopharmacology · 2024 · PMID:37369776

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-03 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on my research of circuit-level neural dynamics in neurodegeneration, I present 6 novel therapeutic hypotheses targeting specific circuit dysfunctions:

Hypothesis 1: Differential Interneuron Optogenetic Restoration Therapy

Title: Selective SST/PV Interneuron Circuit Rebalancing

Description: Amyloid-β oligomers specifically disrupt somatostatin-positive (SST) and parvalbumin-positive (PV) interneurons, causing differential impairment of theta and gamma oscillations respectively. A dual-target optogenetic therapy could selectively restore SST interneuron function for theta

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Based on my analysis of the literature and critical evaluation of these hypotheses, I'll provide a rigorous scientific critique of each:

Hypothesis 1: Differential Interneuron Optogenetic Restoration Therapy

Specific Weaknesses:

Temporal precision problem: The hypothesis assumes static dysfunction, but interneuron impairment is progressive and heterogeneous across brain regions

Delivery limitations: Optogenetic therapy requires viral vectors and implanted devices, creating significant translational barriers

Oversimplified oscillation-function relationship: The

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment of Circuit-Level Neurodegeneration Hypotheses

Based on my analysis of drug development landscapes, clinical pipelines, and translational barriers, here's my comprehensive assessment:

HYPOTHESIS 1: Differential Interneuron Optogenetic Restoration

Druggability Assessment: POOR

Target Proteins: PVALB (parvalbumin) and SST (somatostatin) are not directly druggable - they're calcium-binding and neuropeptide proteins respectively
Alternative Approaches: Must rely on optogenetic gene therapy targeting interneuron populations

**Exist

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▼ 100.0%

Volatility

Low

0.0000

Events (7d)

Clinical Trials (8) Relevance: 51%

0
Active

0
Completed

1,633
Total Enrolled

PHASE1
Highest Phase

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function PHASE1

COMPLETED · NCT00526968 · Evotec Neurosciences GmbH

19 enrolled · 2007-09 · → 2007-12

The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.

Human Volunteers

EVT 101 EVT 101 placebo

The Dortmund Vital Study: Impact of Biological and Lifestyle Factors on Cognitive Performace and Work Ability N/A

ACTIVE_NOT_RECRUITING · NCT05155397 · Technical University of Dortmund

627 enrolled · 2016-04 · → 2035-12

The goal of the Dortmund Vital Study is to validate previous hypotheses and to generate and validate new hypotheses about the relationship of ageing, working conditions, genetic makeup, stress, metabo

Age-related Cognitive Decline

DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil N/A

COMPLETED · NCT02711683 · First Affiliated Hospital Xi'an Jiaotong University

92 enrolled · 2016-03 · → 2019-12

Alzheimer's disease (AD) is the commonest cause of dementia. There is no effective treatment to cure the disease. Cholinesterase inhibitors, such as donepezil, are widely recommended to patients with

Alzheimer's Disease

DL-3-n-butylphthalide Donepezil

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) PHASE3

COMPLETED · NCT03391882 · Sumitomo Pharma America, Inc.

113 enrolled · 2018-12-19 · → 2021-08-11

A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with P

Motor OFF Episodes Associated With Parkinson's Disease

APL-130277 subcutaneous apomorphine

Protective Anesthesiological Management Procedure Imposes Control on Respiratory Comlications NA

UNKNOWN · NCT06282003 · Masa Kontic

53 enrolled · 2023-10-10 · → 2024-06-30

Anesthetic effects, surgery, and invasive mechanical intubation can impair respiratory function during general anesthesia. The risk factors for postoperative pulmonary complications (PPCs) include the

Well-Being, Psychological

The procedure of protective lung ventilation

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD PHASE3

COMPLETED · NCT02168127 · Rhodes Pharmaceuticals, L.P.

360 enrolled · 2014-05 · → 2015-05

The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.

ADHD

Drug: PRC-063 PRC-063

5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor N/A

COMPLETED · NCT02632370 · Constantinos Hadjipanayis

69 enrolled · 2016-05 · → 2018-12-31

In support of the US marketing application for 5-ALA, this single arm trial is being conducted to establish the efficacy and safety of Gliolan® (5-ALA) in patients with newly diagnosed or recurrent ma

Malignant Gliomas

Gliolan® Fluorescence-Guided Surgery

Magnetic Resonance Imaging of Brain Development in Autism N/A

UNKNOWN · NCT00449566 · UMC Utrecht

300 enrolled · 2006-01

The purpose of this study is to investigate brain development in autism by longitudinally assessing children with autism, as well as typically developing controls, using advanced MR techniques. We wil

Autism

📚 Cited Papers (19)

Functional integrity of thalamocortical circuits differentiates normal aging from mild cognitive impairment.

Human brain mapping (2010) · PMID:19449329

No extracted figures yet

Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression.

Proceedings of the National Academy of Sciences of the United States of America (2013) · PMID:23431156

No extracted figures yet

The distinct role of NR2B subunit in the enhancement of visual plasticity in adulthood.

Molecular brain (2016) · PMID:26282667

No extracted figures yet

NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (Aβ) overexpressing mice.

Acta neuropathologica communications (2019) · PMID:30352630

No extracted figures yet

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2023) · PMID:37369776

No extracted figures yet

Molecular mechanism of ligand gating and opening of NMDA receptor.

Nature (2024) · PMID:39085540

No extracted figures yet

Synaptic rearrangement of NMDA receptors controls memory engram formation and malleability in the cortex.

Science advances (2024) · PMID:39213354

No extracted figures yet

Epigenetics in Learning and Memory.

Sub-cellular biochemistry (2025) · PMID:39820860

No extracted figures yet

Inspired by molecular dynamic simulation, exploring chemical constituents of alcoholic extract of Garuga pinnata computationally as inhibitors of GluN2B-containing NMDA receptors.

Journal of biomolecular structure & dynamics (2026) · PMID:40166865

No extracted figures yet

Cognitive loss after brain trauma results from sex-specific activation of synaptic pruning processes.

Brain (2026) · PMID:40796363

No extracted figures yet

Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil.

Brain (2026) · PMID:40994429

No extracted figures yet

Mechanism of conductance control and neurosteroid binding in NMDA receptors.

Nature (2025) · PMID:41162707

No extracted figures yet

📓 Linked Notebooks (1)

📓 Circuit-level neural dynamics in neurodegeneration — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-03-26abc5e5f9f2. Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit di …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Origin

crossover · gen 2

parent: h-var-e2b5a7e7db × h-var-7c976d9fb7

→ Browse all arenas & tournaments

KG Entities (89)

APOE APOE4 APP AQP4 Alzheimer's disease BDNF CA1 CA3 CAMK2A CDK5 CHAT CSF1R CaMKII CaMKII_protein GABAergic interneuron networks GAD1 GRIN2B GluN2B modulation GluN2B_receptor HDAC

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration

Score: 0.990 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.950 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration

Score: 0.907 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration

Score: 0.892 | neurodegeneration

H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Pruning to Amyloid Clearance

Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost

$2M

Timeline

2.0 years

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (111 edges)

activates (1)

BDNF→synaptic_plasticity

associated with (11)

CAMK2A→neuroscienceCHAT→neuroscienceGRIN2B→neuroscienceMAPT→neuroscienceVIP→neuroscience

▸ Show 6 more

SST→Alzheimer's diseasePVALB→Alzheimer's diseaseSST→alzheimer_s_diseasePVALB→alzheimer_s_diseaseBDNF→alzheimer_s_diseasePVALB/SST→neuroscience

▸ Show 15 more

CHAT→GRIN2BCAMK2A→MAPTCHAT→MAPTMAPT→VIPGRIN2B→MAPTBDNF→PVALBPVALB→SSTGRIN2B→VIPBDNF→CA3BDNF→CA1CAMK2A→PVALB/SSTCHAT→PVALB/SSTGRIN2B→PVALB/SSTMAPT→PVALB/SSTPVALB/SST→VIP

co discussed (14)

RAB5→TREM2RAB7→TREM2APP→GAD1GAD1→PSEN1BDNF→PSD95

▸ Show 9 more

APOE4→BDNFBDNF→CSF1RBDNF→TREM2HDAC→PSD95APP→PSD95AQP4→MAPTAPOE→TFEBCDK5→MAPKAQP4→TREM2

disrupts (1)

MAPT→hippocampal_circuit

dysfunction causes (1)

thalamocortical_circuit→cognitive_impairment

encodes (4)

CHAT→choline_acetyltransferaseGRIN2B→GluN2B_receptorMAPT→tau_proteinCAMK2A→CaMKII_protein

expressed in (3)

VIP→VIP_interneuronsPVALB→PV_interneuronsSST→SST_interneurons

generates (4)

PV_interneurons→gamma_oscillationsSST_interneurons→theta_oscillationsPVALB→gamma_oscillationSST→theta_oscillation

implicated in (8)

SST→neurodegenerationPVALB→neurodegenerationh-cd60e2ec→neuroscienceh-f8316acf→neuroscienceh-23b94ed8→neuroscience

▸ Show 3 more

h-62c78d8b→neuroscienceh-a635d4e5→neuroscienceh-7110565d→neuroscience

investigated in (4)

diseases-psp→h-var-6612521a02diseases-corticobasal-syndrome→h-var-9c0368bb70diseases-ftd→h-var-3b982ec3d2diseases-vascular-cognitive-impairment→h-var-6612521a02

involved in (3)

SST→gabaergic_interneuron_networksPVALB→prefrontal_inhibitory_circuitsBDNF→hippocampal_neurogenesis_and_synaptic_plasticity

modulates (3)

VIP_interneurons→default_mode_networkGluN2B_receptor→thalamocortical_circuitGRIN2B→thalamocortical_synchrony

participates in (2)

SST→GABAergic interneuron networksPVALB→Prefrontal inhibitory circuits

promoted: Gamma entrainment therapy to restore hippocampal-cortical synchrony (1)

SST→Alzheimer's disease

promoted: Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation (1)

BDNF→Alzheimer's disease

promoted: Prefrontal sensory gating circuit restoration via PV interneuron enhancement (1)

PVALB→Alzheimer's disease

promotes (1)

CaMKII_protein→synaptic_plasticity

propagates through (1)

tau_protein→locus_coeruleus_hippocampus_pathway

regulates (1)

SST→gamma_oscillation

studied in (3)

SST→neurosciencePVALB→neuroscienceBDNF→neuroscience

targets (7)

h-cd60e2ec→GRIN2Bh-f8316acf→PVALBh-f8316acf→SSTh-23b94ed8→MAPTh-62c78d8b→CAMK2A

▸ Show 2 more

h-a635d4e5→VIPh-7110565d→CHAT

therapeutic target (3)

SST→Alzheimer's diseasePVALB→Alzheimer's diseaseBDNF→Alzheimer's disease

Mechanism Pathway for TREM2

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    RAB5["RAB5"] -->|co discussed| TREM2["TREM2"]
    RAB7["RAB7"] -->|co discussed| TREM2_1["TREM2"]
    BDNF["BDNF"] -->|co discussed| TREM2_2["TREM2"]
    AQP4["AQP4"] -->|co discussed| TREM2_3["TREM2"]
    style RAB5 fill:#ce93d8,stroke:#333,color:#000
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style RAB7 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_1 fill:#ce93d8,stroke:#333,color:#000
    style BDNF fill:#ce93d8,stroke:#333,color:#000
    style TREM2_2 fill:#ce93d8,stroke:#333,color:#000
    style AQP4 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_3 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 TREM2 — PDB 6YXY Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Circuit-level neural dynamics in neurodegeneration

neuroscience | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance

Hypotheses from Same Analysis (8)

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

3D Protein Structure

Dimension Scores

✓ Supporting Evidence 16

✗ Opposing Evidence 3

Hypothesis 1: Differential Interneuron Optogenetic Restoration Therapy

Hypothesis 1: Differential Interneuron Optogenetic Restoration Therapy

Practical Feasibility Assessment of Circuit-Level Neurodegeneration Hypotheses

HYPOTHESIS 1: Differential Interneuron Optogenetic Restoration

Druggability Assessment: POOR

**Exist

Price History

Clinical Trials (8) Relevance: 51%

📚 Cited Papers (19)

📓 Linked Notebooks (1)

⚔ Arena Performance

Origin

KG Entities (89)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions

Knowledge Subgraph (111 edges)

activates (1)

associated with (11)

catalyzes (1)

causes (CaMKII enhancement promotes dendrite ramification ) (1)

causes (CaMKII-dependent process that promotes spine gener) (1)

causes (NMDA receptors mediate synaptic depression in amyl) (1)

causes (VIP interneuron-mediated disinhibition allows pyra) (1)

causes (loss of natural sensory input leads to degeneratio) (1)

causes (optogenetic activation selectively restores gamma ) (1)

causes (optogenetic activation selectively restores theta ) (1)

causes (selective modulation of GluN2B-containing NMDA rec) (1)

causes (selective noradrenaline depletion exacerbates syna) (1)

causes (specifically disrupt parvalbumin-positive interneu) (1)

causes (specifically disrupt somatostatin-positive interne) (1)

causes (tau pathology spreads from locus coeruleus to hipp) (1)

co associated with (20)

co discussed (14)

disrupts (1)

dysfunction causes (1)

encodes (4)

expressed in (3)

generates (4)

implicated in (8)

investigated in (4)

involved in (3)

modulates (3)

participates in (2)

promoted: Gamma entrainment therapy to restore hippocampal-cortical synchrony (1)

promoted: Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation (1)

promoted: Prefrontal sensory gating circuit restoration via PV interneuron enhancement (1)

promotes (1)

propagates through (1)

regulates (1)

studied in (3)

targets (7)

therapeutic target (3)

Mechanism Pathway for TREM2

3D Protein Structure

Source Analysis

Circuit-level neural dynamics in neurodegeneration

Community Feedback